HIV
An Introduction to HIV
HIV infection has been a major global problem since its emergence in 1981. Antiretroviral drugs revolutionized the treatment and prevention of HIV, but adherence and the impact on quality of life are ongoing challenges. New longer-acting treatments have recently been introduced to help address these issues, and evolving treatments with a novel mode-of-action are currently under investigation.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Our supporting partners do not constitute an endorsement of the content on this page.
Celebrating the next generation of innovators in infectious diseases Following the success of the 2025 Future Leaders, touchINFECTIOUS DISEASES is delighted to launch nominations for the Future Leaders 2026 initiative. The infectious diseases landscape continues to evolve rapidly, driven by emerging pathogens, ...
Dr Shibani Mukerji discusses practical approaches to assessing and managing cognitive ageing in people living with HIV As people living with HIV are living longer, cognitive health is becoming an increasingly important component of long-term care. Traditional diagnostic frameworks, such ...
Discover how the latest data from CROI 2026 is shaping clinical practice and future directions in HIV care The 2026 Conference on Retroviruses and Opportunistic Infections (CROI) showcased a rapidly evolving HIV landscape, with a clear shift towards treatment simplification, long-acting innovation ...
Exploring the role of community-generated data in identifying service gaps and strengthening HIV health systems Solange Baptiste, Executive Director at ITPC Global, explores the critical role of community-generated data in strengthening HIV prevention and health systems monitoring, presented at ...
Although single-tablet regimens (STR) have transformed HIV care by simplifying treatment and improving adherence, a substantial number of patients remain on complex multi-tablet therapies due to resistance, tolerability issues or drug–drug interactions. Simplifying treatment while maintaining durable viral suppression ...
In this interview, Dr Eric Meissner (The Medical University of South Carolina, Charleston, SC, USA) discusses the Phase III results from the ARTISTRY-2 study evaluating the investigational STR combining bictegravir and lenacapavir. This novel approach pairs an integrase strand transfer inhibitor with a first-in-class capsid inhibitor.
Despite the success of antiretroviral therapy (ART) in achieving durable viral suppression, HIV persists in long-lived cellular reservoirs that remain a major barrier to cure. Among these, T follicular helper (Tfh) cells within lymph nodes represent an important tissue reservoir ...
Presented at CROI 2026, Prof. Jürgen Rockstroh (Universitätsklinikum Bonn, Bonn, Germany) discusses week 48 results from the Phase III MK-8591A-053 study comparing DOR/ISL (100/0.25 mg) with BIC/FTC/TAF in treatment-naïve adults with HIV-1.
In this practice pearl, we talked with Dr Lydia Efobi (University of Nigeria, Nsukka, Nigeria), an early-career HIV specialist as she reflects on where stigma persists in modern practice. She outlines practical, people-centred approaches to dismantling it within everyday HIV care.
HIV persistence remains a central barrier to achieving durable viral remission, yet the immunological mechanisms that sustain infected cells within tissues continue to challenge the field. In this Q&A, Prof. Michael R Betts (Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA) discusses how decades of work in HIV immunology have shaped current understanding of CD8 T-cell function, tissue-based immunoregulation and the cellular features of the HIV reservoir, presented at the Centre of Excellence for Spatial Multi-Omics Research in Africa (CESORA) 2025 Symposium.
It is my pleasure to introduce this issue of touchREVIEWS in Infectious Diseases for 2025, which features a diverse range of reviews and editorials addressing the scientific, clinical and policy dimensions of infectious disease management in a rapidly evolving global landscape. ...
In this Q&A, Dr Andrew Hill (University of Liverpool, Liverpool, UK) discusses new findings from the updated analysis of lenacapavir manufacturing costs, pricing disparities and real-world barriers to global implementation.
In this Q&A, Dr Monica Gandhi shares her insights on the most impactful HIV therapeutic developments, how clinicians can optimize integrase inhibitor use, which patients benefit most from long-acting or simplified regimens, and key findings from EACS 2025.
The STI & HIV World Congress is the leading global forum on sexually transmitted infections (STIs), HIV, and sexual health. Jointly organized by the International Society for Sexually Transmitted Diseases Research (ISSTDR) and the International Union Against Sexually Transmitted Infections (...
“Successful long-acting injectable implementation is built on patient choice and teamwork, empowering both patients and providers to find what works best for each individual.” - Dr Moti Ramgopal Long-acting injectable (LAI) therapies are transforming HIV prevention and treatment by improving ...
At IDWeek 2025, Dr Moti Ramgopal presented the first proof-of-concept clinical trial of pirmitegravir (STP0404), an allosteric integrase inhibitor (ALLINI) with a unique mechanism of action and potential to address integrase strand transfer inhibitor (INSTI) resistance in HIV treatment.
At the start of 2025, the world was healthier and safer because of the USA’s longstanding commitment to biomedical research.1–3 Further progress was on the horizon as healthcare providers delivered new interventions targeting the leading infectious causes of illness and ...
People living with HIV (PLWH) are living longer, healthier lives due to the effectiveness of antiretroviral therapy (ART) and sustained viral suppression.1–4 Studies conducted in Europe and North America indicate that individuals who initiate ART early and achieve adequate immune ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
